Risperdal News

Free Case Review

Although Risperdal received FDA approval to treat the symptoms of schizophrenia, recent news about the drug suggests that it may not be the safest form of treatment available. In 2003, Risperdal manufacturer Janssen Pharmaceutica Products announced that they would be contacting thousands of doctors warning of a possible link between Risperdal use and stroke in elderly patients.

The 2003 announcement followed a 2002 warning by Janssen to Canadian physicians. The 2002 warning reported 37 stroke or stroke-like events, including 16 deaths. In 2004, Janssen sent a letter to the healthcare community explaining the potential health risks associated with Risperdal. This letter followed extensive criticism by the medical community and the public that Janssen was deceptive in their advertising and promotion of the drug.

Risperdal has been prescribed for more than eight years to over 10 million people worldwide. It is the most popular drug used to treat schizophrenia, but several high-profile lawsuits have demonstrated the health risks associated with Risperdal. The drug is particularly hazardous to children and the elderly. Such risks prompted the FDA to become involved and require warning labels on Risperdal and other antipsychotic drugs.

Risperdal News Stories:

[Antipsychotics and hyperpolactinaemia: pathophysiology, clinical relevance, diagnosis and therapy].

Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater , Vol.

Yeah TEAM-- Final Score: Correct Diagnosis 1, Bipolar Children Diagnosis 0

A long-running NIMH initiative, the Treatment of Early Age Mania study presented its most recent scientific paper on October 21st, 2011, at the annual meeting of the American Academy of Child and Adolescent Psychiatry in Toronto, Canada and published its findings online at the website of the Archives of General Psychiatry ... (more)

Genetic Link to Child Complications from Antipsychotic Drugs

Investigators discovered the genetic variation can cause a six-fold greater risk for children to develop metabolic syndrome.

Risperidone and the whistle that no one heard

Splashing the headlines this week is a settlement reached between Johnson and Johnson and the state of Texas.

Head-to-head comparisons of metabolic side effects of second...

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis by: Christine Rummel-Kluge , Katja Komossa , Sandra Schwarz , Heike Hunger , Franziska Schmid , Claudia A. Lobos , Werner Kissling , John M. Davis , Stefan Leucht The metabolic side effects ... (more)